Impel Pharmaceuticals Total Current Liabilities

Impel Pharmaceuticals (IMPL) currently reports a total current liabilities of $120M as of September 2023. That compares with $20M in the prior-year period — up 524.9% year over year. Use the charts on this page to explore Impel Pharmaceuticals's total current liabilities history and peer comparisons.

Impel Pharmaceuticals's total current liabilities increased from $20M to $120M — a 524.9% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Impel Pharmaceuticals reported $120M in total current liabilities as of September 2023. That compares with $20M in the prior-year period — up 524.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $120M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Impel Pharmaceuticals, and consider following IMPL for alerts when major investors trade the stock.

Impel Pharmaceuticals is classified in the Healthcare sector. On total current liabilities, it currently shows $120M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMPL with unrelated industries.